Recent and emerging anti-diabetes targets.
Diabetes is a disease that affects over 150 million people worldwide for which there are multiple oral and injectable medications. Because of trends in obesity and sedentary lifestyles, diabetes rates in both developed and developing countries are increasing at an alarming rate. Current medications are not adequately effective in maintaining long-term glycemic control in most patients, even when used in combination, leaving diabetics susceptible to developing life threatening and debilitating complications such as cardiovascular disease, blindness, kidney complications, and amputations. Consequently, there is a critical need for more potent pharmacotherapies with novel mechanisms of action. A panel of 20 emerging diabetes targets is presented, and small molecule modulators for each target will be discussed.
Preclinical Research and Development, GTx, Inc., 3 N. Dunlap Street, Memphis, TN 38163, USA. mmohler@gtxinc.com
Michael L
ML
Mohler
Yali
Y
He
Zhongzhi
Z
Wu
Dong Jin
DJ
Hwang
Duane D
DD
Miller
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry* / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use
D007004:Hypoglycemic Agents